Investor Presentaiton

Executive Summary Top Line Growth with Healthy Profitability 1 2 3 4 Differentiated APIs for key customers and internal commercialization Growth in unbranded markets via complex & limited competition assets Growth in branded markets via differentiated products and services Investment and approvals in biologics (EMS) and Proprietary Products (US) to drive mid to long-term growth Well-positioned for sustained profitable growth given our proven capability in complex generics with strategic investments in R&D for Proprietary Products and Biologics Investor Presentation - 2016 Dr. Reddy's Laboratories Ltd. 6

View entire presentation